Pharmaceutical News

RSS

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Fisetin, a naturally occurring compound found in strawberries and other fruits and vegetables, slows the onset of motor problems and delays death in three models of Huntington's disease, according to researchers at the Salk Institute for Biological Studies. The study, published in the online edition of Human Molecular Genetics, sets the stage for further investigations into fisetin's neuroprotective properties in Huntington's and other neurodegenerative conditions.

16 Nov 2010

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

NPR reports on dengue vaccine progress

NPR's Shots blog examines progress in the search for a vaccine to protect against the dengue virus. WHO estimates that 2.5 billion people worldwide are at risk of getting dengue, and most of them are in Asia and Latin America, the blog writes.

16 Nov 2010

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.

15 Nov 2010

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.

15 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Best ways for proper disposal of unused medicines

Patients in cities all over the country will learn tomorrow about one of the best ways to avoid today's rampant prescription drug abuse – proper disposal of unused medicines.

15 Nov 2010

Research on P450 compound I may help eliminate toxins

Chemical reactions are happening all over the place all the time on the sun, on the Earth and in our bodies. In many cases, enzymes help make these reactions occur. One family of enzymes, called cytochrome P450s (P450), is important because they help us eliminate toxins.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Researchers find influenza vaccines can contain allergenic components

People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.

15 Nov 2010

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.

15 Nov 2010

AMP receives FDA approval to manufacture ophthalmic product using Capmatic Patriot dropper bottle filling line

Alliance Medical Products announced today, at the AAPS Annual Meeting and Exposition, the U.S. Food and Drug Administration (FDA) has granted approval to manufacture a certain commercially available ophthalmic product using the company's high speed dropper bottle filling line.

15 Nov 2010

Study finds children more likely to be allergic to amoxicillin

Children are more likely to have an allergy to amoxicillin than adults, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16. Amoxicillin is a form of penicillin.

15 Nov 2010

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

The Bill & Melinda Gates Foundation has awarded nationally prominent Oregon Health & Science University reproductive scientist Jeffrey T. Jensen, M.D., M.P.H., a $100,000 grant to investigate the safety and effectiveness of a novel low-cost family-planning option that may be applicable to women in low-resource countries worldwide.

15 Nov 2010

Report documents increase in R&D projects on developing world diseases

Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners, according to a report released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

15 Nov 2010

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

There is a simple explanation for most of the mergers and acquisitions in the pharmaceutical world these days the so called Patent Cliff. Simply put, many of the drug industry's biggest earners blockbuster medications that have paid the bills for the last decade are about to lose their patent protections.

15 Nov 2010

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

15 Nov 2010

Acne, acne medicine and mental health: Study

Acne drug Accutane (isotretinoin) has been plagued by serious controversies with some linking it to suicidal tendencies. Now the latest research finds that severe acne itself increases the risk for suicidal thoughts and actions, raising more questions about the role of the drug, if any, in suicide.

14 Nov 2010

Pharmaceutical News

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

FDA approves Halaven therapy for metastatic late-stage breast cancer

RBC boosting drugs may undermine breast cancer treatment with Herceptin

NPR reports on dengue vaccine progress

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Emerging blood thinners to prevent stroke

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Best ways for proper disposal of unused medicines

Research on P450 compound I may help eliminate toxins

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Researchers find influenza vaccines can contain allergenic components

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

AMP receives FDA approval to manufacture ophthalmic product using Capmatic Patriot dropper bottle filling line

Study finds children more likely to be allergic to amoxicillin

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

Report documents increase in R&D projects on developing world diseases

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

Labopharm receives notice about Activis' ANDA for OLEPTRO

Acne, acne medicine and mental health: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News